Search Results - "Merck"

Low-density lipoprotein cholesterol drives multinucleated giant cell formation in response to mycobacterium bovis Bacille Calmette-Guérin.

Authors: Merck, Philipp-Alexander Lösslein, Anne Kathrin Neuber, Jana et al.

Source: Scientific Reports. 1/7/2026, Vol. 16 Issue 1, p1-11. 11p.

Engineering Students' Perceptions of Mathematical Modeling in a Learning Module Centered on a Hydrologic Design Case Study

Authors: Merck, Madeline F. Gallagher, Melissa A. Habib, Emad et al.

Source: International Journal of Research in Undergraduate Mathematics Education. Jul 2021 7(2):351-377.

Peer Reviewed: Y

Page Count: 27

Sponsoring Agency: National Science Foundation (NSF), Division of Undergraduate Education (DUE)
National Oceanic and Atmospheric Administration (DOC)

Descriptors: Engineering Education, Mathematical Models, Mathematics Skills, Skill Development, Learning Modules, Electronic Learning, Instructional Effectiveness, Design, Case Method (Teaching Technique), Water, Authentic Learning, Problem Based Learning, Technology Integration, College Students, Student Attitudes

The European Union's International Obligations Regarding Trade with Occupied Territories: A Case Study of Western Sahara Litigation Before the cjeu.

Authors: Merck Giuliani, Emanuela¹ (AUTHOR) emanuela.merckgiuliani@echr.coe.int

Source: Journal of International Humanitarian Legal Studies. 2026, Vol. 17 Issue 1, p145-182. 38p.

The Stanford Bridge Project: Maryland Community College Extension.

Authors: Stanford Univ., CA. Stanford Inst. for Higher Education Research. MacLellan, Ann Merck Gandy, Kathleen House

Peer Reviewed: N

Page Count: 29

Sponsoring Agency: Office of Educational Research and Improvement (ED), Washington, DC.
National Center for Postsecondary Improvement, Stanford, CA.

Descriptors: Academic Achievement, Articulation (Education), Community Colleges, Educational Assessment, Educational Objectives, Enrollment, High School Students, Student Placement, Transfer Policy, Transfer Programs, Transfer Students, Two Year Colleges

Geographic Terms: Maryland

The Design of School Improvement in Schools on Probation: A Comparative Content Analysis of School Improvement Plans in Three Accountability Systems.

Authors: Mintrop, Heinrich MacLellan, Ann Merck Quintero, Margaret Fee et al.

Peer Reviewed: N

Page Count: 68

Descriptors: Accountability, Comparative Analysis, Competency Based Education, Educational Change, Educational Improvement, Educational Technology, Elementary Secondary Education, Instructional Improvement, Management by Objectives, Motivation Techniques, Performance Based Assessment, Power Structure, Probationary Period, Public Schools, Systems Analysis

Geographic Terms: Kentucky, Maryland

DICOM Image ANalysis and Archive (DIANA): an Open-Source System for Clinical AI Applications.

Authors: Yi, Thomas Pan, Ian Collins, Scott et al.

Source: Journal of Digital Imaging; Dec2021, Vol. 34 Issue 6, p1405-1413, 9p, 3 Diagrams, 1 Chart, 2 Graphs

The Salinity of the Great Salt Lake and Its Deep Brine Layer.

Authors: Merck, Madeline F. Tarboton, David G.

Source: Water (20734441). Apr2023, Vol. 15 Issue 8, p1488. 18p.

From Minneapolis to Westminster.

Authors: Merck, Mandy

Source: Critical Quarterly; Summer92, Vol. 34, p32-42, 11p

Nonspecific Effects of Normal Aging on Taxonomic and Thematic Semantic Processing.

Authors: Merck, Catherine Noël, Audrey Jamet, Eric et al.

Source: Experimental Aging Research. Jan/Feb2023, Vol. 49 Issue 1, p18-40. 23p. 1 Diagram, 3 Charts, 2 Graphs.

Subjects: Semantic memory, Aging

THE PLEASURES AND CHALLENGES OF DEGROWTH: A CONVERSATION WITH KATE SOPER.

Authors: Highmore, Ben Merck, Mandy Taylor, Jenny Bourne

Source: New Formations; 2022, Issue 107/108, p215-229, 15p

EXTINCTION AND THE ANTHROPOCENE: TO END OR MEND THE WORLD? A CONVERSATION WITH CLAIRE COLEBROOK.

Authors: Bennett, David Gilbert, Jeremy Merck, Mandy et al.

Source: New Formations; 2022, Issue 107/108, p198-214, 17p

Neutrosophic Statistic for Exploratory Analysis of the Data Provided by the Publications in the Social Sciences.

Authors: Benavides Benalcázar, Merck Milko Narváez Montenegro, Bolívar David Calderón Velásquez, María José et al.

Source: Neutrosophic Sets & Systems. 2021, Vol. 44, p289-298. 10p.

Merck’s LIPFENDRA® (enlicitide) is the First and Only Once-Daily Oral PCSK9 Inhibitor Approved by the U.S. FDA to Reduce LDL-C in Adults with Hypercholesterolemia

Authors: Merck & Co., Inc.

Source: Business Wire (English). 07/16/2026.

Merck to Present New Data on Daily, Weekly, and Monthly Options Across its HIV Treatment and Prevention Pipeline at AIDS 2026

Authors: Merck & Co., Inc.

Source: Business Wire (English). 07/15/2026.

KEYTRUDA® (pembrolizumab) as Monotherapy Significantly Improved Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer With Mismatch Repair Deficient (dMMR) Tumors Compared to Chemotherapy

Authors: Merck & Co., Inc.

Source: Business Wire (English). 07/15/2026.

FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each With Padcev® (enfortumab vedotin-ejfv), as Treatment Before and After Surgery for Adults With Muscle-Invasive Bladder Cancer (MIBC)

Authors: Merck & Co., Inc.

Source: Business Wire (English). 07/10/2026.

Merck to Hold Second-Quarter 2026 Sales and Earnings Conference Call Aug. 4

Authors: Merck & Co., Inc.

Source: Business Wire (English). 07/01/2026.

Merck Announces New Agreement with ADAP Crisis Task Force to Improve Access and Care for People Living with HIV

Authors: Merck & Co., Inc.

Source: Business Wire (English). 06/29/2026.

FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), each with Trodelvy® (sacituzumab govitecan-hziy) as First-Line Treatment of PD-L1+ (CPS ≥10) Advanced Triple-Negative Breast Cancer (TNBC)

Authors: Merck & Co., Inc.

Source: Business Wire (English). 06/25/2026.

European Commission Approves KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as First PD-1 Inhibitor Plus Antibody-Drug Conjugate Regimen for Adults With Cisplatin-Ineligible Resectable Muscle-Invasive Bladder Cancer

Authors: Merck & Co., Inc.

Source: Business Wire (English). 06/24/2026.